S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Quotient Stock Price, News & Analysis (NASDAQ:QTNT)

$8.12
-0.35 (-4.13 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$8.06
Now: $8.12
$8.55
50-Day Range
$7.06
MA: $8.11
$9.02
52-Week Range
$5.52
Now: $8.12
$11.30
Volume230,903 shs
Average Volume345,310 shs
Market Capitalization$538.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.13 million
Book Value$0.03 per share

Profitability

Net Income$-105,390,000.00
Net Margins-352.75%

Miscellaneous

EmployeesN/A
Market Cap$538.10 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.


Quotient (NASDAQ:QTNT) Frequently Asked Questions

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) announced its earnings results on Monday, August, 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. The business had revenue of $8.17 million for the quarter, compared to the consensus estimate of $8.40 million. View Quotient's Earnings History.

When is Quotient's next earnings date?

Quotient is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Quotient.

What guidance has Quotient issued on next quarter's earnings?

Quotient updated its second quarter 2020 earnings guidance on Monday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.3-6.7 million, compared to the consensus revenue estimate of $6.5 million.

What price target have analysts set for QTNT?

1 Wall Street analysts have issued 1 year target prices for Quotient's stock. Their predictions range from $13.50 to $13.50. On average, they expect Quotient's stock price to reach $13.50 in the next year. This suggests a possible upside of 66.3% from the stock's current price. View Analyst Price Targets for Quotient.

What is the consensus analysts' recommendation for Quotient?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.

Has Quotient been receiving favorable news coverage?

Headlines about QTNT stock have trended somewhat positive on Monday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Quotient earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Quotient.

Are investors shorting Quotient?

Quotient saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,560,000 shares, an increase of 40.3% from the August 30th total of 3,250,000 shares. Based on an average daily volume of 322,700 shares, the short-interest ratio is presently 14.1 days. Currently, 8.0% of the shares of the company are sold short. View Quotient's Current Options Chain.

Who are some of Quotient's key competitors?

What other stocks do shareholders of Quotient own?

Who are Quotient's key executives?

Quotient's management team includes the folowing people:
  • Mr. Franz Walt, CEO & Director (Age 60)
  • Mr. Jeremy Stackawitz, Pres (Age 44)
  • Mr. Edward Farrell, Pres (Age 49)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
  • Mr. John Allan, Corp. Sr. VP & CTO

Who are Quotient's major shareholders?

Quotient's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Quotient stock include Brian Mcdonough, Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Prondzynski Heino Von and Roland Boyd. View Institutional Ownership Trends for Quotient.

Which institutional investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz and Roland Boyd. View Insider Buying and Selling for Quotient.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $8.12.

How big of a company is Quotient?

Quotient has a market capitalization of $538.10 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.

What is Quotient's official website?

The official website for Quotient is http://www.quotientbd.com/.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.


MarketBeat Community Rating for Quotient (NASDAQ QTNT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel